Isis Pharmaceuticals Inc. recently received U.S. Patent No.5,218,105 on novel synthesis methods for oligonucleotideanalogs.
The Carlsbad, Calif., company (NASDAQ:ISIP) said the patentextends and expands Isis' proprietary position inoligonucleotide therapeutic development.
The patent follows U.S. Patent No. 5,138,045, issued in August1992, which covers 5-prime polyamine-conjugatedoligonucleotide analogs.
TRIPLEX GETS EUROPEAN PATENTTriplex Pharmaceutical Corp. has received a patent from theEuropean Patent Office relating to its novel triple helixtechnology for applications in human therapeutics.
A corresponding patent was issued earlier this year by the U.S.Patent Office, the company said. Based in The Woodlands,Texas, Triplex is developing compounds to bind and inhibitdisease-associated genes.
(c) 1997 American Health Consultants. All rights reserved.